Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial
Sıla Gerlevik(London Cancer), Ghulam Mufti(King's College London), Morag Griffin(Leeds Teaching Hospitals NHS Trust), Riley Cook(Centre Hospitalier Universitaire de Toulouse), Deniz Ece Kaya(London Cancer), Marica Laurino(Hospices Civils de Lyon), Austin Kulasekararaj(King's College London), Fiorenza Barraco(Hôpital Lyon Sud), Antonio M. Risitano(European Society for Blood and Marrow Transplantation), Constantijn Halkes(Leiden University Medical Center), Nogayhan Seymen(London Cancer), Camilla Frieri(Université Paris Cité), Sofie Terwel(Centre Hospitalier Universitaire de Toulouse), Mohammad M. Karimi(University of British Columbia), Carlo Dufour(Istituto Giannina Gaslini), Régis Peffault de Latour(Hôpital Saint-Louis), Marleen van Os(Universität Hamburg), Beatrice Drexler(University Hospital of Basel), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Flore Sicre-de-Fontbrune(Hôpital Saint-Louis), Simona Iacobelli(Universität Hamburg), Jean-Baptiste Mear(Université Rennes 2), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Etienne Daguindau(Hôpital Privé Jean Mermo), Giorgio Napolitani(University of Oxford)
Cited by 0
Related Papers
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
|Nature Immunology|2020|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750